Teva

Global Generic Pharmaceuticals Company.

Launch date

1901

Employees

Market cap

Enterprise valuation

€33.6b (Public information from Sep 2024)

Petah Tikva Center District (HQ)

http://www.tevapharm.com

https://twitter.com/tevapharm https://www.facebook.com/tevapharm https://www.linkedin.com/company/teva-pharmaceuticals/

View job openings

Revenues, earnings & profits over time

USD	2019	2020	2021	2022	2023	2024	2025
Revenues	16.9b	16.7b	15.9b	14.9b	15.8b	16.2b	16.8b
% growth	(8 %)	(1 %)	(5 %)	(6 %)	6 %	2 %	3 %
EBITDA	3.2b	4.6b	4.5b	4.1b	4.3b	-	-
% EBITDA margin	19 %	28 %	29 %	28 %	27 %	-	-
Profit	(999m)	(4.0b)	417m	(2.4b)	(559m)	-	-
% profit margin	(6 %)	(24 %)	3 %	(16 %)	(4 %)	-	-
R&D budget	1.0b	997m	967m	838m	953m	-	-
R&D % of revenue	6 %	6 %	6 %	6 %	6 %	-	-

Date	Investors	Amount	Round
-	Royalty Pharma	N/A	-
Feb 1982	N/A	N/A	IPO
Feb 2010	N/A	N/A	IPO
Feb 2018	Berkshire Hathaway	$358m	Post IPO Equity
Dec 2023*	Affinity Asset Advisors	$12.0m	Post IPO Equity
Total Funding		-

Tech stackLearn more about the technologies and tools that this company uses.

exited

exited

ACQUISITION by Roche Dec 2017

ACQUISITION by Teva Jul 2015

Cocrystal Discovery

ACQUISITION by Biozone Pharmaceuticals Jan 2014

ACQUISITION by Teva May 2011

Heptares Therapeutics

ACQUISITION by Sosei Group Feb 2015

Auspex Pharmaceuticals

ACQUISITION by Teva Mar 2015

exited